Philippines Liver Cancer Therapeutics Market Report 2022 to 2030

Philippines Liver Cancer Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Philippines liver cancer therapeutics market will reach a value of $24.4 Mn from $6.45 Mn in 2022, growing at a CAGR of 18.1% during 2022-30. The liver cancer therapeutics market in the Philippines is dominated by a few domestic pharmaceutical companies such as United Laboratories, Pascual Laboratories, and Philippine Pharma Resources. The liver cancer therapeutics market in the Philippines is segmented into different types of cancer and different therapy type. Some of the major factors affecting this market are the growing prevalence of liver cancer and the high cost and side effects related to certain liver cancer therapies.

ID: IN10PHPH039 CATEGORY: Pharmaceuticals GEOGRAPHY: Phillipines AUTHOR: Dr. Vishwa Modhia

Buy Now

Philippines Liver Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the Philippines liver cancer therapeutics market will reach a value of $24.4 Mn from $6.45 Mn in 2022, growing at a CAGR of 18.1% during 2022-30.

The Philippines is a low-middle-income developing country in Southeast Asia in the western Pacific Ocean. Liver cancer is the fifth most prevalent cancer among males and the ninth most common cancer among women. In 2018, there were about 840,000 new cases. According to the World Cancer Research Fund and the American Institute for Cancer's Continuous Update Project Panel, the Philippines ranks 23rd among the Top 25 countries with the highest incidence of liver cancer in 2018.

According to the most recent WHO data, 7,663 people died from liver cancer in the Philippines in 2020, accounting for 1.14 % of all fatalities. With an age-adjusted death rate of 9.73 per 100,000 people, the Philippines ranks 30th in the world. The Philippines government spent 5.1 % of its GDP on healthcare in 2020.

philippines liver cancer therapeutics market

Market Dynamics

Market Growth Drivers

In the Philippines, 36 % of all gastrointestinal cancers were caused by alcohol intake. The National Nutrition Council (NNC) has labeled the continuing rise in the number of Filipinos diagnosed with liver ailments, particularly liver cancer, as a "hidden pandemic." Liver cancer is relatively common in the Philippines, owing to the prevalence of cirrhosis of the liver, a key risk factor for liver cancer. The Business Process Outsourcing (BPO) business in the Philippines is flourishing.

Market Restraints

Therapy for liver cancer can be costly, and some patients in the Philippines may lack access to health insurance or financial aid to meet the expense of treatment. This might make it difficult for individuals to obtain and afford the care they require. The Philippines has significant income disparities and underemployment, which drives expatriation.

Competitive Landscape

Key Players

United Laboratories - United Laboratories (UNILAB) is one of the largest pharmaceutical companies in the Philippines. The company produces a range of generic and branded medicines, including oncology drugs. UNILAB produces several medicines for the treatment of liver cancer, including Sorafenib and Lenvatinib
Pascual Laboratories - Pascual Laboratories is another Philippine pharmaceutical company that produces a range of medicines, including oncology drugs
Philippine Pharma Resources - Philippine Pharma Resources is a Philippine-based pharmaceutical company that specializes in the development, manufacturing, and distribution of a range of medicines, including oncology drugs
Interphil Laboratories - Interphil Laboratories is a Philippine-based pharmaceutical company that develops and produces a range of medicines, including oncology drugs
Biofemme

Healthcare Policies and Reimbursement Scenarios

In the Philippines, the regulation of liver cancer therapeutics is overseen by the Food and Drug Administration (FDA), which is responsible for evaluating the safety, efficacy, and quality of all medicines, including those used for the treatment of liver cancer. Regarding reimbursement, the Philippines has a national health insurance system called PhilHealth that provides coverage for a range of liver cancer therapeutics, including chemotherapy, targeted therapy, and immunotherapy.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Philippines Liver Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

Hepatocellular Carcinoma
Cholangio Carcinoma
Hepatoblastoma
Other Types

By Treatment (Revenue, USD Billion):

Chemotherapy
Immunotherapy
Targeted Therapy
Radiation Therapy
Ablation Therapy
Embolization Therapy

By Equipment (Revenue, USD Billion):

Computed Radiography
MRI
Sonography
Others

By Route of Administration (Revenue, USD Billion):

Oral
Intravenous

By End User (Revenue, USD Billion):

Hospitals
Clinics
Ambulatory Surgical Centers

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.